What Is Cagrilintide?
Cagrilintide is a amylin analogue supplied by Peptegrity for research and educational purposes. This page provides a factual educational overview of Cagrilintide, including its classification, biological target, research background, terminology and published study context. It is not a product page and does not provide dosing instructions, treatment recommendations or personal-use guidance.
Type of compound
Cagrilintide is a long-acting acylated analogue of the human hormone amylin [1]. It belongs to the class of amylin receptor agonists designed to interact with the calcitonin receptor and receptor activity-modifying proteins [1].
Biological target and mechanism
The compound functions by activating amylin receptors in the central nervous system, which are involved in the regulation of satiety and energy metabolism [1]. Research investigates its role in modulating feeding behavior through these specific receptor pathways [2].
Research background
Cagrilintide was developed to address the short half-life and physical instability of native human amylin through structural modifications [1]. Its research primarily focuses on its potential to influence metabolic markers and weight management in controlled scientific settings [2].
Current research and development status
Cagrilintide is currently an investigational compound and is not approved by the FDA, EMA, or other regulatory bodies for human therapeutic use. It is being evaluated in various phase 2 and phase 3 clinical research trials to assess its safety and physiological effects [2][3][4][5].
Published research context
Published studies have focused on the characterization of the molecule's pharmacokinetic profile and its effects when administered alone or in combination with other peptides like semaglutide [1][3]. Recent research includes large-scale trials investigating the combined administration of cagrilintide and semaglutide in populations with obesity or type 2 diabetes [4][5].
Relevant terminology
Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells that plays a role in glycemic regulation. An analogue is a compound that is structurally similar to another but has modified chemical properties to enhance stability or biological activity in research applications.
Storage and handling terminology
As a peptide, cagrilintide is typically stored in a lyophilized state at low temperatures, such as -20°C or -80°C, to ensure long-term chemical stability. Researchers must handle the material in controlled laboratory environments to prevent degradation caused by moisture, heat, or repeated freeze-thaw cycles.
Testing and Certificate of Analysis (COA)
A Certificate of Analysis (COA) is a document issued by a laboratory that confirms the chemical identity and purity of the research compound, typically verified using techniques like High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). Researchers should verify that the COA provided with the material meets the specific purity requirements for their intended experimental model.
Regulatory status
Cagrilintide is classified as a research chemical intended solely for laboratory use and is not an approved medication for any condition. It may not be distributed or sold for use in humans or for the treatment of any medical disorder.
This page is for research and educational purposes only. It is not intended to provide medical advice, dosing instructions, or treatment recommendations, and does not represent any product as approved to diagnose, treat, cure or prevent any disease. Compounds described here may be investigational or unapproved medicines; regulatory status is summarised for information only.
Frequently asked questions
What is Cagrilintide?
Cagrilintide is a synthetic, long-acting analogue of the naturally occurring hormone amylin, designed for use in scientific and clinical research settings [1].
How is Cagrilintide classified?
It is classified as an amylin analogue and a selective amylin receptor agonist [1].
What is the regulatory status of Cagrilintide?
Cagrilintide is currently an investigational substance. It has not received approval from regulatory authorities such as the FDA or TGA for clinical or medical use.
Has Cagrilintide been studied in combination with other compounds?
Yes, research has investigated the co-administration of cagrilintide with semaglutide to examine potential synergistic effects in metabolic research models [3][4][5].
References
- 1.Development of Cagrilintide, a Long-Acting Amylin AnaloguePubMed
- 2.Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trialScienceDirect
- 3.Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trialPubMed
- 4.Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine
- 5.Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 DiabetesNew England Journal of Medicine
